The influence of superdisintegrant choice on the rate of drug dissolution - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The influence of superdisintegrant choice on the rate of drug dissolution

Pharmaceutical Technology Europe
Volume 21, Issue 9

Discriminatory dissolution profiles

Drug dissolution profiles are increasingly used to evaluate drug release characteristics of pharmaceutical products. The dissolution media adopted by the pharmacopoeias or recommended by the FDA for in vitro dissolution testing are designed to maximize drug release for a given drug. Thus, for a given marketed drug, the recommended medium becomes the quality control standard to assure batch to batch consistency, and ensure continuing product quality and performance are maintained should changes be made to the manufacturing process.

Although the recommended media for in vitro dissolution testing can be used to guide formulation development, it is typically nondiscriminatory between formulation ingredients, as drug release with a poorly soluble drug is usually driven more by the medium than by formulation ingredients.

Discriminatory dissolution profiles are highly desirable for distinguishing between products with differences in pharmaceutical attributes (formulation and/or manufacturing process differences).5

Table 2: Dissolution media tested for drugs with varying degrees of aqueous solubility.
In the present study, dissolution testing was conducted in the recommended media for the drug (the US Pharmacopeia or FDA recommended medium), as well as in modified dissolution media designed to produce drug release profiles that discriminate between formulations with different superdisintegrants. The discriminating media were selected with at least one formulation achieving 80% drug release. The recommended and discriminating media for each drug tested are shown in Table 2.

Tablet physical properties

For a given drug, the formulations were produced using the same process, ingredients and ingredient levels. Tablets were prepared at the highest market dose using a direct compression or wet granulation process, as considered appropriate through a review of the ingredients listed in the Physician's Desk Reference and patent literature. In addition, tablets were compressed to equivalent tablet breaking force to minimize the impact of the tablet's physical properties on the dissolution results. Only the selection of superdisintegrant varied.

With the 13 poorly soluble drugs evaluated, no significant differences were observed in the breaking force and disintegration times of the tablets prepared using the various superdisintegrants for a given drug studied. The full results can be viewed by visiting:

Choice impacts dissolution

Table 3: T80 values of drugs tested in different dissolution media.
The t80 results for all 13 drugs studied in both media are shown in Table 3. As examples, the dissolution profiles for the tablets with atorvastatin in the recommended and discriminating media are shown in Figures 1 and 2.

Figure 1: Dissolution profile for 80 mg Atorvastatin tablets in recommended media.
In the recommended media, crospovidone Type A and Type B provided the fastest t80 for 12 of the 13 drugs studied, while crospovidone Type B provided the fastest t80 for 10 of the 13 drugs studied.

Figure 2: Dissolution profile for 80 mg Atorvastatin tablets in discriminating media.
In the discriminating media, crospovidone Type B provided the fastest release for 12 of 12 drugs — a discriminating medium for raloxifene HCl tablets was not developed as the recommended medium was sufficiently discriminating; hence only 12 drugs were evaluated in a discriminatory medium.

The dissolution profiles indicate that the tablets with crospovidone Type B in both the recommended and discriminating media had the fastest rate of dissolution.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here